Featured

Race Oncology is pleased to announce that Professor Borje Andersson has agreed to chair Race’s

Race Oncology has revealed its new “5 Path” clinical development strategy for its cancer drug,

Prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has

Race Oncology Limited is pleased to announce the successful completion of a $1.45 million

Race Oncology has announced it has secured a new patent on its cancer drug, Bisantrene, from

Race Oncology is pleased to announce the first patient has been treated with Bisantrene in the

Race Oncology has announced the US Food and Drug Administration has received its

Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal

Race Oncology is pleased to announce that it has executed a consulting agreement with Professor